On this page

What Is Cardiomyopathy?
What Types of Cardiomyopathy Exist?
What Are the Causes?
What Are the Symptoms?
How Is Cardiomyopathy Diagnosed?
How Is Cardiomyopathy Treated?
Prevention and Lifestyle
Living With Cardiomyopathy
When to See a Doctor
Sources and Bibliography

What Is Cardiomyopathy?

The word cardiomyopathy comes from the Greek roots kardia (heart), mys (muscle), and pathos (disease), which literally means a “disease of the heart muscle”. It is an umbrella term encompassing a group of conditions in which the myocardium (the muscular wall of the heart) becomes structurally or functionally abnormal, impairing its ability to pump blood effectively to the rest of the body.

In cardiomyopathy, the heart muscle may undergo a variety of pathological changes. It may enlarge (dilate), thicken (hypertrophy), or stiffen (become rigid), or some combination of these. Regardless of the specific structural change, the end result is a heart that works less effectively than it should.

It is important to understand how cardiomyopathies differ from other forms of heart disease. Cardiomyopathies are primary diseases of the heart muscle itself, as distinct from:

Coronary artery disease (coronary heart disease): caused by blockages in the blood vessels supplying the heart
Valvular heart disease (valvulopathies): caused by structural abnormalities of the heart’s valves
Congenital heart disease: structural heart defects present from birth

This distinction matters clinically because different heart diseases require different diagnostic approaches and treatments. However, the distinction is not always absolute. For example, longstanding coronary artery disease can eventually lead to ischemic cardiomyopathy, and cardiomyopathy can secondarily affect the function of the heart valves.

How Cardiomyopathy Affects the Heart

As cardiomyopathy progresses, the diseased heart muscle loses its ability to perform its three fundamental functions:

Efficient pumping: The heart becomes weaker or less efficient, unable to deliver sufficient oxygenated blood to the body’s organs and tissues. This state is called heart failure and is one of the most important consequences of cardiomyopathy.
Electrical regularity: The structural changes in the diseased myocardium disrupt the normal electrical conduction system of the heart. This can lead to the development of arrhythmias: abnormal heart rhythms ranging from relatively benign palpitations to potentially life-threatening ventricular fibrillation.
Valvular function: As the heart’s chambers enlarge or stiffen, the heart valves may no longer close or open properly, leading to secondary valvular dysfunction (such as mitral regurgitation) that further burdens the failing heart.

Potential Complications

The complications of cardiomyopathy can be severe and life-threatening:

Thrombus (blood clot) formation: The poorly functioning, dilated, or arrhythmic heart creates conditions favorable for blood clot formation inside the cardiac chambers. These clots can travel (embolize) to the brain, causing stroke (ictus), or to other organs, causing infarction.
Cardiac arrest: A life-threatening emergency in which the heart suddenly and unexpectedly stops pumping blood effectively, typically due to a malignant arrhythmia such as ventricular fibrillation.
Sudden cardiac death: Unexpected death occurring within one hour of the onset of cardiac symptoms, most commonly due to a fatal arrhythmia. Certain forms of cardiomyopathy, particularly hypertrophic cardiomyopathy, are the leading cause of sudden cardiac death in young people and athletes.

Despite the seriousness of these potential complications, it is equally important to emphasize that many patients with cardiomyopathy live long, fulfilling lives with appropriate medical management. Advances in pharmacological therapy, device-based treatments, and, in extreme cases, cardiac transplantation have dramatically improved outcomes over the past three decades.

What Types of Cardiomyopathy Exist?

Cardiomyopathies are classified into several distinct subtypes based on the nature of the structural and functional changes affecting the heart muscle. Each type has its own causes, clinical behavior, and treatment approach.

The Three Major Forms

1. Dilated Cardiomyopathy (DCM)

Dilated cardiomyopathy is the most common form, accounting for the majority of cardiomyopathy diagnoses. In DCM, the left ventricle (the heart’s main pumping chamber) and often the right ventricle as well become abnormally enlarged (dilated), and their walls become thin and weak. The result is a “baggy”, poorly contracting heart that cannot generate sufficient force to pump blood effectively.

The hallmark of DCM is reduced left ventricular ejection fraction (LVEF), meaning the percentage of blood pumped out of the left ventricle with each heartbeat is significantly below normal (less than 50–55%). This reduced ejection fraction is the defining feature of heart failure with reduced ejection fraction (HFrEF).

DCM is responsible for a large proportion of all heart failure cases and is the single most common indication for cardiac transplantation. It may arise from genetic mutations, viral infections, chronic alcohol abuse, chemotherapy, or numerous other causes, or it may be idiopathic (no identifiable cause found).

2. Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy is an inherited disease in which the heart muscle, most commonly the left ventricular wall and the interventricular septum, becomes abnormally thickened (hypertrophied). Unlike hypertrophy caused by hypertension or athletic training, the hypertrophy in HCM is caused by genetic mutations affecting proteins of the cardiac sarcomere (the heart muscle’s contractile unit) and is not a response to external demands.

The thickened heart muscle:

Becomes stiff and fails to relax normally during diastole (the filling phase), causing diastolic dysfunction
May obstruct the flow of blood out of the left ventricle through the aortic valve (hypertrophic obstructive cardiomyopathy, HOCM)
Creates an abnormal electrical substrate that predisposes to potentially fatal ventricular arrhythmias

HCM is the leading cause of sudden cardiac death in people under 35 years of age, including competitive athletes. However, many patients with HCM have few or no symptoms and lead entirely normal lives. Management depends on symptom severity and arrhythmic risk stratification.

3. Restrictive Cardiomyopathy (RCM)

Restrictive cardiomyopathy is the least common of the three major forms. In RCM, the heart muscle loses its normal elasticity and becomes rigid, not because of hypertrophy or dilation but because normal cardiac muscle is progressively replaced or infiltrated by abnormal material such as scar tissue, amyloid protein deposits, iron, granulomas, or other substances.

The stiffened ventricles cannot relax and expand normally during diastole, impairing ventricular filling. Ejection fraction (systolic function) may be relatively preserved initially, but filling pressures rise dramatically, causing fluid to back up into the lungs and peripheral tissues.

RCM is often associated with systemic diseases such as amyloidosis, sarcoidosis, and hemochromatosis. Its prognosis is generally less favorable than other cardiomyopathy forms, partly because diagnosis is often delayed until the disease is already advanced.

Less Common Forms

Beyond the three major subtypes, several less common forms of cardiomyopathy are recognized:

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Also called arrhythmogenic right ventricular dysplasia (ARVD), this is a rare inherited cardiomyopathy in which the muscle tissue of the right ventricle is progressively replaced by fatty and fibrous tissue. This replacement disrupts the right ventricular architecture and creates an abnormal electrical substrate highly prone to life-threatening ventricular arrhythmias, particularly during physical exertion. ARVC is an important cause of sudden cardiac death in young athletes. It is caused by mutations in genes encoding desmosomal proteins, the proteins that anchor cardiomyocytes to one another. The most commonly affected gene is PKP2 (plakophilin-2).

Diagnosis requires a combination of electrocardiographic findings, cardiac imaging (MRI is the cornerstone), family history, and genetic testing, using the revised Task Force Criteria. Management focuses on arrhythmia prevention (e.g., ICD implantation in high-risk patients, beta-blockers, and antiarrhythmic drugs), lifestyle modification (such as restriction from competitive sports, which accelerates disease progression), and cardiac transplantation in end-stage disease.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin amyloid cardiomyopathy is an increasingly recognized form of cardiomyopathy caused by the deposition of amyloid fibrils derived from the transthyretin (TTR) protein, a transport protein produced by the liver, in the heart wall. It exists in two forms:

Wild-type (wtATTR): occurs with aging (predominantly in men over 70) due to age-related misfolding of normal TTR; previously called “senile cardiac amyloidosis”, it is increasingly recognized as a major under-diagnosed cause of heart failure in older adults
Hereditary (hATTR): caused by inherited mutations in the TTR gene; the Val122Ile variant is particularly prevalent among people of West African descent

ATTR-CM typically presents as a restrictive cardiomyopathy with preserved ejection fraction, progressive heart failure, and is often associated with carpal tunnel syndrome, lumbar spinal stenosis, and peripheral neuropathy (particularly in hATTR). The diagnosis has been transformed by nuclear scintigraphy with bone-avid tracers (99mTc-DPD, 99mTc-PYP, 99mTc-HMDP), which provides a highly sensitive and specific non-invasive means of identifying ATTR amyloid deposition in the heart. The disease has also become specifically treatable with tafamidis, a TTR-stabilizer that significantly reduces mortality and hospitalizations, making early diagnosis a clinical priority.

Stress Cardiomyopathy (Takotsubo Syndrome / “Broken Heart Syndrome”)

Stress cardiomyopathy, also known as Takotsubo syndrome or “broken heart syndrome”, is a transient (reversible) form of cardiomyopathy triggered by an intense physical or emotional stressor. It is characterized by sudden, temporary ballooning and weakening of the left ventricular apex, while the base of the heart continues to contract normally. This pattern is described as “apical ballooning”.

The name “Takotsubo” comes from the Japanese word for a type of octopus-catching pot with a narrow neck and wide base, which resembles the shape of the affected left ventricle on angiography.

Stress cardiomyopathy predominantly affects postmenopausal women (approximately 90% of reported cases) and is typically triggered by:

Intense emotional stress (such as bereavement, relationship breakdown, or fear, hence the “broken heart” nickname)
Intense physical stress (serious illness, surgery, sepsis, stroke)

The good news is that the condition is typically reversible: ventricular function usually recovers fully within days to weeks of the triggering event with supportive care. However, the acute phase can be life-threatening, presenting with chest pain, breathlessness, and sometimes cardiogenic shock or malignant arrhythmias. Recurrence is possible, occurring in approximately 5–10% of patients.

What Are the Causes?

The causes of cardiomyopathy are diverse, and the underlying etiology varies significantly between the different subtypes. The most fundamental distinction is between:

Congenital (primary) cardiomyopathy: present from birth or arising from inherited genetic mutations
Acquired (secondary) cardiomyopathy: developing as a consequence of another disease process, environmental exposure, or lifestyle factor

In many patients, particularly children with cardiomyopathy, the underlying cause remains unidentified (idiopathic) despite comprehensive investigation.

Genetic and Hereditary Causes

A significant proportion of cardiomyopathies, particularly hypertrophic, dilated (familial DCM), and ARVC, are caused by inherited mutations in genes encoding cardiac proteins. These mutations may be passed from parent to child in an autosomal dominant pattern (where a single copy of the mutated gene is sufficient to cause disease), meaning each child of an affected parent has a 50% probability of inheriting the mutation.

Key genetic associations include:

HCM: mutations in sarcomere protein genes (MYH7, MYBPC3, TNNT2, TNNI3, and others)
Familial DCM: mutations in TTN (titin), LMNA (lamin A/C), SCN5A, and others
ARVC: mutations in desmosomal protein genes (PKP2, DSP, DSG2, DSC2, JUP)
ATTR cardiomyopathy: mutations in the TTN gene (hATTR)

Acquired and Secondary Causes

Several well-defined conditions and exposures can cause or contribute to cardiomyopathy:

Cardiovascular and hemodynamic causes:

Untreated high blood pressure (hypertension): chronic pressure overload causes the left ventricle to hypertrophy initially, eventually leading to dilation and failure
Myocardial infarction (heart attack): ischemic damage and scarring from a heart attack is the most common cause of dilated cardiomyopathy in Western countries
Untreated persistent tachycardia: sustained rapid heart rates (e.g., uncontrolled atrial fibrillation with fast ventricular response) can cause reversible “tachycardia-induced cardiomyopathy”
Valvular heart disease: longstanding abnormalities of the heart valves create pressure or volume overload that eventually damages the myocardium

Metabolic and endocrine causes:

Obesity: excess body weight places increased hemodynamic demands on the heart and promotes adverse cardiac remodeling
Thyroid disorders: both hyperthyroidism (overactive thyroid) and hypothyroidism (underactive thyroid) can impair myocardial function
Diabetes mellitus: diabetic cardiomyopathy is a recognized entity driven by chronic hyperglycemia, insulin resistance, and metabolic dysfunction
Metabolic syndrome: the combination of obesity, hypertension, dyslipidemia, and insulin resistance creates a hostile metabolic environment for the heart

Toxic and iatrogenic causes:

Chemotherapy: certain cancer drugs, particularly anthracyclines (such as doxorubicin and epirubicin), are directly cardiotoxic and can cause DCM. Newer targeted therapies, including trastuzumab and tyrosine kinase inhibitors, also carry cardiac risks.
Radiation therapy: thoracic irradiation can cause myocardial fibrosis and restrictive cardiomyopathy, often years or decades after treatment.
Chronic alcohol abuse: a major preventable cause of dilated cardiomyopathy, directly toxic to cardiac muscle cells
Illicit drugs: cocaine, methamphetamine, and anabolic steroids can cause severe cardiomyopathy.

Infiltrative and systemic diseases:

Sarcoidosis: granulomatous infiltration of the myocardium
Amyloidosis: deposition of abnormal protein fibrils in the heart (AL or ATTR)
Hemochromatosis: excessive iron accumulation in the myocardium

Infectious and inflammatory causes:

Viral myocarditis: viral infections (Coxsackievirus B, parvovirus B19, HIV, adenovirus) can directly damage cardiac muscle cells and trigger an inflammatory process that leads to DCM
Parasitic infections: Trypanosoma cruzi (causing Chagas disease) is a major cause of cardiomyopathy in Latin America
Bacterial and fungal myocarditis: less common but recognized causes

Nutritional causes:

Severe deficiencies of thiamine (vitamin B1), selenium, or carnitine can impair myocardial energy metabolism and cause cardiomyopathy

Lifestyle factors play a central role in the development of acquired cardiomyopathy and represent the most impactful domain for primary prevention (see Prevention and Lifestyle section below).

What Are the Symptoms?

Cardiomyopathy does not always cause symptoms, particularly in early stages or in milder forms of the disease. Many patients are diagnosed incidentally when an ECG or echocardiogram performed for an unrelated reason reveals structural or functional abnormalities. However, as the disease progresses and the heart’s ability to compensate diminishes, symptoms of heart failure and arrhythmia typically emerge and progressively worsen.

The specific symptoms experienced, and their severity, vary significantly between individuals and between different types of cardiomyopathy. The following symptoms may develop, typically becoming more prominent in advanced disease:

Respiratory Symptoms

Fatigue and breathlessness (dyspnea): This is typically the earliest and most prominent symptom. Initially, patients notice breathlessness only during exertion. Physical activities that previously seemed effortless become increasingly difficult. As the disease progresses, breathlessness occurs with even minimal activity (getting dressed, walking a short distance) and eventually at rest. This escalation reflects progressively worsening pulmonary congestion as blood backs up from the failing heart into the lungs.
Orthopnea: Difficulty breathing when lying flat, forcing the patient to sleep propped up on multiple pillows. Caused by redistribution of fluid from the legs to the lungs when lying down.
Paroxysmal nocturnal dyspnea: Episodes of severe breathlessness that awaken the patient from sleep, typically 1–2 hours after going to bed.
Cough when lying down: A persistent cough in the recumbent position, sometimes producing frothy or blood-tinged sputum in severe pulmonary edema.

Fluid Retention and Congestion

Swelling of the legs, ankles, and feet (peripheral edema): Caused by elevated venous pressure and fluid leaking from the blood vessels into the surrounding tissues. Edema is typically worse at the end of the day and after prolonged standing, and improves overnight with leg elevation.
Abdominal bloating and distension: Caused by fluid accumulation in the abdominal cavity (ascites) and congestion of abdominal organs, particularly the liver (which may cause right upper quadrant discomfort) and the bowel (which can lead to nausea, bloating, and reduced appetite).
Unexplained weight gain: Rapid weight gain (more than 1–2 kg over 1–2 days) due to fluid retention is a key early warning sign of decompensating heart failure and should always be reported to the healthcare team.

Cardiac Symptoms

Palpitations and tachycardia: An uncomfortable awareness of the heartbeat, described as racing, fluttering, pounding, or skipping. This is caused by arrhythmias that commonly develop in cardiomyopathy. These range from benign ectopic beats to clinically significant arrhythmias such as atrial fibrillation or ventricular tachycardia.
Chest discomfort or tightness: A sensation of pressure, heaviness, or constriction in the chest, which may reflect myocardial ischemia (insufficient blood supply to the heart muscle) or elevated filling pressures.

Neurological and Systemic Symptoms

Fatigue and weakness: Chronic, debilitating fatigue, even with minimal exertion, is extremely common in cardiomyopathy. It reflects the heart’s inability to deliver adequate oxygenated blood to the muscles and vital organs. Many patients describe a gradual but relentless erosion of their exercise tolerance and activity levels.
Dizziness and lightheadedness: May occur due to reduced cardiac output, hypotension (low blood pressure), or arrhythmias causing transient reduction of blood flow to the brain.
Syncope (fainting): Sudden, transient loss of consciousness caused by a dramatic reduction in cerebral blood flow. In cardiomyopathy, syncope is particularly concerning when it occurs during physical exertion (which may signal a dangerous arrhythmia) and warrants prompt specialist evaluation.

The Spectrum of Severity

It is important to emphasize that symptoms exist on a spectrum of severity:

Some patients remain entirely asymptomatic for years or decades
Others experience mild symptoms that fluctuate and do not significantly interfere with daily life
Many patients develop progressively worsening symptoms that severely limit functional capacity
In some cases (particularly in hypertrophic cardiomyopathy and ARVC), the first manifestation of the disease may be a life-threatening arrhythmia or cardiac arrest, occurring without prior warning symptoms

The New York Heart Association (NYHA) functional classification is widely used in clinical practice to categorize the severity of heart failure symptoms:

Class I: No symptoms with ordinary activity
Class II: Mild symptoms with moderate exertion; comfortable at rest
Class III: Symptoms with minimal exertion; comfortable only at rest
Class IV: Symptoms at rest; unable to perform any physical activity without discomfort

How Is Cardiomyopathy Diagnosed?

The diagnosis of cardiomyopathy involves a systematic, stepwise process that begins with clinical assessment and proceeds to confirmatory cardiac imaging and specialized testing. The goals of the diagnostic workup are to:

Confirm the presence of cardiomyopathy and define its type
Identify the underlying cause, particularly those that are treatable or reversible
Assess the severity and functional impact of the disease
Identify complications (arrhythmias, thrombi, valve disease)
Risk-stratify the patient for arrhythmic events and sudden cardiac death
Guide treatment decisions

Step 1: Clinical History and Physical Examination

The first and foundational step is a thorough clinical history (anamnesis) and physical examination. The physician asks about:

The onset, nature, and progression of symptoms
Past medical history (known cardiovascular disease, infections, autoimmune disease, cancer and cancer treatments)
Family history of heart disease, cardiomyopathy, sudden cardiac death, or heart transplantation in relatives
Detailed medication history (including chemotherapy agents)
Lifestyle factors: alcohol and drug use, diet, physical activity, smoking history
Travel history (relevant for Chagas disease and endomyocardial fibrosis)

Physical examination provides valuable clinical information, including signs of heart failure (elevated jugular venous pressure, lung crackles, peripheral edema, gallop rhythm, cardiac murmurs) and extra-cardiac manifestations of systemic diseases that cause cardiomyopathy.

Step 2: Diagnostic Investigations

Depending on the clinical findings, one or more of the following investigations are performed:

Blood Tests

Laboratory testing provides important information about the patient’s overall health status, identifies potential causes of cardiomyopathy, and quantifies the severity and impact of the disease:

BNP or NT-proBNP: natriuretic peptides are released by the stretched ventricular myocardium; markedly elevated levels are highly sensitive and specific for heart failure and correlate with its severity. They are used both for diagnosis and for monitoring treatment response.
Cardiac troponins (I and T): markers of myocardial cell injury; elevation suggests ongoing cardiomyocyte damage
Complete blood count: to exclude anemia (which worsens heart failure) and detect inflammatory markers
Renal function: kidney impairment is both a cause and consequence of heart failure
Thyroid function (TSH, free T4): to exclude thyroid disease as a contributing cause
Iron studies and ferritin: for hemochromatosis screening and iron deficiency assessment
Serum protein electrophoresis and serum free light chains: to screen for AL amyloidosis
Alpha-galactosidase A enzyme activity: in men with unexplained LV hypertrophy, to screen for Fabry disease
Genetic testing panels: next-generation sequencing covering known cardiomyopathy-associated genes, particularly when a familial or genetic cause is suspected

Chest X-Ray (Radiograph)

A plain chest X-ray provides rapid initial information about:

Heart size: cardiomegaly (enlarged cardiac silhouette) is characteristic of dilated cardiomyopathy; the heart may be normal-sized in hypertrophic and restrictive cardiomyopathy
Pulmonary congestion: upper lobe blood diversion, interstitial edema, and pleural effusions indicate elevated left-sided filling pressures
Pericardial calcification: may suggest constrictive pericarditis as an alternative diagnosis

Electrocardiogram (ECG)

The electrocardiogram (ECG) is one of the simplest and most informative initial investigations. In cardiomyopathy, the ECG may reveal:

Left ventricular hypertrophy (increased QRS voltage)
Left bundle branch block: associated with DCM and dyssynchronous contraction
Low voltage: characteristic of cardiac amyloidosis
Pathological Q waves: suggesting prior myocardial infarction (ischemic cardiomyopathy) or infiltrative disease
Atrial fibrillation or other arrhythmias
Repolarization abnormalities: ST-segment and T-wave changes

Prolonged ambulatory ECG monitoring (Holter monitoring, over 24–48 hours or longer) is used to detect intermittent arrhythmias not captured on a resting ECG.

Echocardiogram (Cardiac Ultrasound)

The echocardiogram is the cornerstone of cardiomyopathy diagnosis and the most important single investigation. It is non-invasive, widely available, safe, and provides real-time information about:

Left ventricular size and volumes: dilated in DCM, normal or reduced in HCM and RCM
Left ventricular ejection fraction (LVEF): the most important measure of systolic (pump) function; reduced in DCM (HFrEF), typically preserved in HCM and early RCM
Wall thickness: increased in HCM; normal in DCM; may be normal or mildly thickened in RCM
Diastolic function: assessment of the ventricle’s ability to relax and fill; impaired in HCM and RCM
Valve function: detection of secondary mitral regurgitation, aortic stenosis, or other valvular abnormalities
Left ventricular outflow tract (LVOT) obstruction: present in obstructive HCM
Pericardium: to differentiate from constrictive pericarditis
Right ventricular size and function: important in ARVC and pulmonary hypertension

Nuclear Scintigraphy

Scintigraphy using bone-avid radiotracer agents (99mTc-DPD, 99mTc-PYP, 99mTc-HMDP) has become a key diagnostic tool for transthyretin (ATTR) amyloid cardiomyopathy. These radiotracers bind selectively to ATTR amyloid deposits in the myocardium, producing a characteristic pattern of cardiac uptake on nuclear imaging. This pattern is highly sensitive and specific for ATTR-CM, which allows a non-invasive diagnosis in most cases without requiring cardiac biopsy.

Cardiac Magnetic Resonance Imaging (MRI)

Cardiac MRI is the gold standard for myocardial tissue characterization, which is the ability to identify the nature of the abnormal material within the heart muscle. It provides:

Precise measurement of ventricular volumes, mass, and ejection fraction
Late gadolinium enhancement (LGE): identifies areas of myocardial fibrosis, scarring, and infiltration with characteristic patterns for different etiologies (ischemic vs. non-ischemic DCM, HCM, amyloidosis, sarcoidosis, myocarditis)
T1 mapping and extracellular volume (ECV): quantitative markers of diffuse myocardial fibrosis and amyloid deposition
T2 mapping: detects myocardial edema and inflammation (useful in acute myocarditis)
T2 mapping*: quantifies myocardial iron content in hemochromatosis

Coronary Angiography and Cardiac Catheterization

Coronary angiography visualizes the coronary arteries to determine whether obstructive coronary artery disease is contributing to (or causing) the cardiomyopathy, an important distinction because ischemic cardiomyopathy may be amenable to revascularization. Invasive cardiac catheterization directly measures intracardiac pressures and is the gold standard for differentiating restrictive cardiomyopathy from constrictive pericarditis.

Angiography may also be used to assess pulmonary pressures and cardiac hemodynamics in complex cases.

Stress Testing

Exercise stress testing (treadmill or bicycle ergometer, with or without imaging) helps objectively quantify exercise capacity, unmask symptoms or hemodynamic abnormalities not present at rest, risk-stratify patients, and guide treatment decisions.

How Is Cardiomyopathy Treated?

Treatment of cardiomyopathy is highly individualized, depending on the type, the underlying cause, the severity of symptoms, and the presence of complications. While a complete cure is generally not possible for most forms of cardiomyopathy, the goals of treatment are:

Control symptoms and improve quality of life
Slow or halt disease progression
Prevent and manage complications (arrhythmias, thromboembolism, heart failure decompensation)
Reduce the risk of sudden cardiac death
Extend survival

Some patients, particularly those with mild disease, no symptoms, or a fully reversible cause (such as tachycardia-induced cardiomyopathy or hemochromatosis detected early), may require no specific treatment beyond monitoring and lifestyle modification. Others require intensive, multimodal management.

Lifestyle Changes

Lifestyle modifications are foundational to management across all cardiomyopathy subtypes and are often profoundly underestimated in their impact:

Dietary sodium restriction (to 2–3 grams per day) reduces fluid retention and the burden on the failing heart
Daily weight monitoring: tracking weight each morning allows early detection of fluid accumulation
Moderate, regular physical activity: tailored to the individual’s functional capacity and cardiomyopathy subtype; cardiac rehabilitation programs offer supervised exercise with multidisciplinary support
Achieving and maintaining a healthy weight: reduces hemodynamic burden and metabolic stress on the heart
Complete avoidance of alcohol (particularly important in alcoholic cardiomyopathy)
Smoking cessation: essential for all patients
Avoidance of illicit drugs: cocaine, amphetamines, and anabolic steroids are directly cardiotoxic
Optimal management of coexisting conditions: rigorous control of hypertension, diabetes, and hyperlipidemia

Pharmacological Treatment

The medications used in cardiomyopathy management depend on the specific type and the dominant clinical manifestations:

For heart failure with reduced ejection fraction (HFrEF, primarily in DCM), the four evidence-based pillars of modern therapy are:

RAAS inhibitors: ACE inhibitors (enalapril, ramipril, lisinopril) or ARBs (valsartan, candesartan), or preferably the combined ARNI sacubitril/valsartan (Entresto®), which has been shown superior to ACE inhibitors in reducing cardiovascular death and hospitalization
Beta-blockers (carvedilol, bisoprolol, metoprolol succinate): reduce heart rate, arrhythmic risk, and adverse cardiac remodeling
Mineralocorticoid receptor antagonists (MRAs): spironolactone or eplerenone; reduce fluid retention and myocardial fibrosis
SGLT2 inhibitors (dapagliflozin, empagliflozin): originally developed for diabetes; have been shown to significantly reduce cardiovascular death and heart failure hospitalizations in HFrEF regardless of diabetic status

Additional agents include:

Diuretics (diuretics): loop diuretics (furosemide, torasemide) are used to relieve congestion and edema, which is essential for symptom control.
Beta-blockers: slow the heart rate, reduce blood pressure, and control arrhythmias.
Digoxin: increases cardiac contractility; may improve rate control in atrial fibrillation.
Anticoagulants: essential in patients with atrial fibrillation (to prevent stroke) and in those with intracardiac thrombus; direct oral anticoagulants (DOACs) are generally preferred.
Antiarrhythmic drugs: amiodarone, sotalol, and other agents to control symptomatic arrhythmias.
Disease-specific agents: tafamidis for ATTR amyloidosis; corticosteroids for cardiac sarcoidosis; phlebotomy and iron chelation for hemochromatosis; mavacamten (Camzyos®) for symptomatic obstructive HCM; disopyramide for obstructive HCM.

Surgical Interventions and Implantable Devices

In more severe cases, surgical procedures or implantable devices may be necessary:

Implantable cardioverter-defibrillator (ICD): a device implanted under the skin connected to leads in the heart that continuously monitors the heart rhythm and delivers a life-saving shock if a life-threatening arrhythmia (ventricular fibrillation or tachycardia) occurs. It is the most effective way to prevent sudden cardiac death in high-risk cardiomyopathy patients.
Cardiac resynchronization therapy (CRT / biventricular pacemaker): a specialized pacemaker that coordinates the contraction of both ventricles simultaneously, improving pump efficiency in patients with significant dyssynchrony (abnormally wide QRS on ECG, particularly left bundle branch block). CRT can dramatically improve symptoms and survival in appropriately selected DCM patients.
Pacemaker implantation: for patients who develop significant bradycardia (slow heart rate) or heart block as a complication of cardiomyopathy (particularly cardiac sarcoidosis and lamin A/C mutation-associated DCM).
Septal myectomy (for obstructive HCM): surgical removal of hypertrophied septal muscle to relieve left ventricular outflow tract obstruction; provides excellent, durable symptom relief in experienced centers with operative mortality below 1%.
Alcohol septal ablation (for obstructive HCM): a minimally invasive catheter-based procedure using targeted alcohol injection to reduce septal hypertrophy; an alternative to myectomy in patients unsuitable for surgery.
Left ventricular assist device (LVAD): a mechanical pump implanted inside the chest to support the failing left ventricle; used as a bridge to transplantation, bridge to recovery, or destination therapy in end-stage cardiomyopathy.
Catheter ablation: for arrhythmias (atrial fibrillation, ventricular tachycardia) that are refractory to drug therapy; particularly important in cardiac sarcoidosis and ARVC.

Heart Transplantation

In patients with end-stage cardiomyopathy (severe, progressive heart failure with a very limited life expectancy despite optimal medical and device therapy), cardiac transplantation remains the definitive treatment option. It offers the possibility of dramatically improved survival and quality of life. Eligibility criteria are stringent and include absence of other severe systemic conditions, appropriate age (typically under 60–65), and psychosocial suitability for complex post-transplant care.

Prevention and Lifestyle

For acquired cardiomyopathy, lifestyle plays a central role in both prevention and disease management. While genetic cardiomyopathy cannot be prevented, many risk factors for acquired forms are modifiable. Key protective lifestyle factors include:

Regular physical activity: moderate-intensity aerobic exercise (150–300 minutes per week as per general guidelines) reduces cardiovascular risk, improves metabolic health, and supports heart function
A varied, balanced diet: rich in fruits, vegetables, whole grains, and lean proteins; low in sodium, saturated fats, and added sugars
Maintaining a healthy body weight: avoiding obesity reduces the hemodynamic, metabolic, and inflammatory burden on the heart
Avoiding smoking: tobacco is a major independent cardiovascular risk factor
Limiting or avoiding alcohol: chronic excess alcohol is a direct cause of cardiomyopathy and worsens all other forms of heart disease
Avoiding illicit drugs: cocaine, amphetamines, and anabolic steroids are cardiotoxic
Adequate management of chronic conditions: rigorous control of hypertension, diabetes, thyroid disease, and other cardiovascular risk factors is among the most effective preventive strategies for acquired cardiomyopathy

For patients with known genetic risk (family history of cardiomyopathy or identified familial mutation), regular cardiac surveillance, including periodic ECG and echocardiography at a specialist cardiomyopathy center, allows early detection of emerging disease before symptoms or complications develop.

Living With Cardiomyopathy

A diagnosis of cardiomyopathy is life-changing, but with appropriate care, many patients live active and rewarding lives for many years. Living well with cardiomyopathy requires active engagement in self-management, regular specialist follow-up, and access to comprehensive multidisciplinary support.

Self-Management Essentials

Daily weight monitoring: weigh yourself every morning at the same time (before eating, after voiding). Report weight gains of more than 1–2 kg in 1–2 days to your healthcare team immediately.
Sodium-restricted diet: limiting salt intake reduces fluid retention and helps control symptoms.
Medication adherence: heart failure medications are complex, and their benefits often take time to become apparent. Never stop or change your medications without consulting your doctor.
Know your warning signs: recognize the symptoms that require urgent medical attention (see section below).
Regular follow-up appointments: cardiomyopathy requires lifelong specialist monitoring.

Emotional and Psychological Wellbeing

A diagnosis of a chronic, potentially serious heart condition inevitably affects psychological wellbeing. Anxiety, depression, and fear about physical limitations, disease progression, sudden cardiac death, and the impact on family members are common and should be acknowledged and addressed. Many specialist cardiomyopathy centers offer access to:

Psychologists or counselors experienced with cardiac patients
Cardiac rehabilitation programs (combining exercise, education, and psychological support)
Patient support groups and peer networks

Family Considerations

For patients with inherited cardiomyopathy (HCM, familial DCM, ARVC), family screening is a critical component of care. All first-degree relatives should be offered cardiac evaluation (ECG and echocardiogram) and, where a causative mutation has been identified, genetic testing. Early detection in asymptomatic family members allows preventive measures to be implemented before complications occur.

When to See a Doctor

You should seek urgent medical attention if you experience any of the following:

Sudden, severe shortness of breath, particularly at rest or when lying flat
Rapid, unexplained weight gain (more than 1–2 kg over 1–2 days)
New or worsening leg or ankle swelling
Palpitations or fast, irregular heartbeat, especially if associated with dizziness, lightheadedness, or near-fainting
Syncope (loss of consciousness), particularly if it occurs during or just after physical exertion
Chest pain or tightness that is new, severe, or different from what you have experienced before
Symptoms of stroke: sudden facial asymmetry, arm weakness, speech difficulty, or sudden severe headache
Any ICD shock: always seek medical evaluation after a shock from an ICD, even if you feel well

You should also schedule a routine medical consultation if you have not yet been screened and have a first-degree relative diagnosed with cardiomyopathy, or if you have unexplained breathlessness, fatigue, or edema that is new or gradually worsening.

Sources and Bibliography

American Heart Association – What is Cardiomyopathy in Adults?
Mayo Clinic – Cardiomyopathy: Symptoms and Causes
McDonagh TA, et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421.
Elliott P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270–276.
Maron BJ, et al. Contemporary Definitions and Classification of the Cardiomyopathies. Circulation. 2006;113(14):1807–1816.
Ommen SR, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;76(25):e159–e240.
Maurer MS, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007–1016.
Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017;390(10092):400–414.
Corrado D, et al. Arrhythmogenic Right Ventricular Cardiomyopathy: Evaluation, Treatment, and Prevention of Sudden Death. J Am Coll Cardiol. 2017;69(15):1954–1963.
Lyon AR, et al. 2022 ESC Guidelines on Cardio-Oncology. Eur Heart J. 2022;43(41):4229–4361.
Templin C, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med. 2015;373:929–938.
McMurray JJV, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF). N Engl J Med. 2014;371:993–1004.
McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). N Engl J Med. 2019;381:1995–2008.

Cardiomyopathy: Meaning, Types, Causes, Symptoms, and Treatment